Agios Pharmaceuticals (AGIO) Other Non-Current Liabilities (2012 - 2026)

Agios Pharmaceuticals has reported Other Non-Current Liabilities for 8 years, with the latest figure at $90000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 89.77% year-over-year to $90000.0; the trailing twelve-month figure through Mar 2026 stood at $90000.0 (down 89.77% YoY), and the FY2025 full-year result was $90000.0, down 89.77% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $90000.0, roughly flat from $90000.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $3.3 million in Q4 2022, with the low at $90000.0 in Q3 2025.
• Historically, Other Non-Current Liabilities has averaged $985562.5 across 5 years, with a median of $1.1 million in 2022.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities climbed 9.57% — and 2025, when it slumped 92.21%.
• Agios Pharmaceuticals' Other Non-Current Liabilities stood at $3.3 million in 2022, then sank by 64.75% to $1.2 million in 2023, then slipped by 23.88% to $880000.0 in 2024, then plunged by 89.77% to $90000.0 in 2025, then changed by 0.0% to $90000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $90000.0 (Q1 2026), $90000.0 (Q4 2025), and $90000.0 (Q3 2025), per Business Quant data.